Aim To study the effects of BPI-1096,a nitric oxide-releasing aspirin,on platelet aggregation. Methods Platelet-rich plasma(PRP) samples was prepared from healthy adult volunteers.The antiaggregant effects of BPI-1096 were tested by a standard nephelometric technique after incubating the drug with platelet at 37℃ for 10 min. Results The platelet aggregation induced by adenosine diphosphate(ADP),platelet activating factor(PAF),adnephrin and restocetin was inhibited by BPI-1096 at different concentration(p<0.05).BPI1096 inhibited platelet aggregation induced by arachidonic acid in every concentration but did ont show any significance(p>0.05).BPI-1096 displayed inhibitory effects similar to ASA at the same concentration.BPI-1096 did not strengthen the inhibitory effects on platelet aggregation at high concentration. Conclusions As a newly nitric oxide-releasing aspirin,BPI-1096 can significantly inhibit platelet aggregation induced by adnephrin,restocetin,ADP and PAF in vitro;the antiaggregation effects was similar to Aspirin at the same concentration.BPI-1096 did not show the correlation between concentration and efficiency.